Drugs · acquisition-cost intelligence
RESTASIS
cyclosporine· ingredient cyclosporineCalcineurin inhibitors· CYCLOSPORINE .5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.52
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other cyclosporine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| CycloSPORINE, Modfied | $0.71770 | −$0.80130 |
| Cyclosporine | $2.35 | +$0.83100 |
| Cyclosporine | $5.58 | +$4.06 |
| Restasis MultiDose | $112.33 | +$110.81 |
| VEVYE | $368.89 | +$367.38 |
Medicare Part D coverage · CY2026
On 185 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 82% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.